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ABSTRACT
LINC00472 is a novel long intergenic non-coding RNA. We evaluated LINC00472 
expression in breast tumor samples using RT-qPCR, performed a meta-analysis of 
over 20 microarray datasets from the Gene Expression Omnibus (GEO) database, 
and investigated the effect of LINC00472 expression on cell proliferation and 
migration in breast cancer cells transfected with a LINC00472-expressing vector. 
Our qPCR results showed that high LINC00472 expression was associated with less 
aggressive breast tumors and more favorable disease outcomes. Patients with high 
expression of LINC00472 had significantly reduced risk of relapse and death compared 
to those with low expression. Patients with high LINC00472 expression also had 
better responses to adjuvant chemo- or hormonal therapy than did patients with low 
expression. Results of meta-analysis on multiple studies from the GEO database were 
in agreement with the findings of our study. High LINC00472 was also associated 
with favorable molecular subtypes, Luminal A or normal-like tumors. Cell culture 
experiments showed that up-regulation of LINC00472 expression could suppress 
breast cancer cell proliferation and migration. Collectively, our clinical and in vitro 
studies suggest that LINC00472 is a tumor suppressor in breast cancer. Evaluating 
this long non-coding RNA in breast tumors may have prognostic and predictive value 
in the clinical management of breast cancer.
INTRODUCTION
Breast cancer is the most common female 
malignancy, annually accounting for more than a million 
new diagnoses worldwide [1]. Although breast cancer 
has been studied extensively for decades, mechanisms of 
tumor progression have remained largely elusive. Tumor 
heterogeneity is a major challenge to understanding 
the disease. Breast cancer varies not only from patient 
to patient, but also within the same tumor. The disease 
evolves over time and changes in response to chemo- and 
hormonal therapies [2–5]. The unstable genome of tumor 
cells is partially responsible for these changes [3, 6, 7]. 
Many studies have been conducted to search for disease 
features that can help to predict disease outcome and 
treatment response, but no robust tumor markers have yet 
been identified.
Proteins are considered to be the major molecules 
carrying out essential biologic actions [8], yet only 2% 
of the human genome contains the codes for proteins. 
Most genomic sequences are now understood to be 
transcribed, though without translation capability [9]. 
These non-protein coding transcripts are involved in many 
biologic processes and cellular activities. Recently, long 
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non-coding RNAs (lncRNAs) were recognized as a 
new class of non-coding RNAs with important biologic 
functions [10–16]. LncRNAs exert their actions through 
interactions with chromatin in the regulation of gene 
expression [17–20], modulation of epigenetic regulation 
pre- and post-transcriptionally [21–23], and influences on 
activities and locations of other functional molecules such 
as proteins and other RNA species [12, 14, 24–29]. Studies 
have shown that disruption of lncRNA action occurs in 
certain diseases including cancer [30–34].
In search of the Gene Expression Omnibus (GEO) 
database from the NCBI website, we found that a novel 
long intergenic non-coding RNA, LINC00472 [35] 
(Supplementary Figure S1), frequently appeared on top 
of the gene transcript lists that are associated with tumor 
grade or disease death in several breast cancer microarray 
datasets. We searched the literature and found no 
information on this lincRNA with regard to its biological 
functions and associations with cancer or other diseases. 
To determine the clinical relevance of LINC00472 in 
breast cancer and to assess its biologic effects on breast 
cancer cells, we measured LINC00472 expression in more 
than 300 breast tumor samples to analyze its association 
with clinical and pathological features of breast cancer, 
conducted a meta-analysis on more than 2 dozens 
independent clinical studies to confirm the findings of our 
clinical study, and transfected a LINC00472 expression 
vector into breast cancer cells to assess the lincRNA’s 
effects on cell growth and migration. In this report, we 
describe the findings of LINC00472 in our clinical study, 
meta-analysis and in vitro experiments.
RESULTS
Clinical study
In the clinical study of 348 tumor samples, high 
LINC00472 expression occurred more often in patients 
with smaller tumors ( p < 0.0001), lower tumor grades 
( p < 0.0001), and earlier stage disease ( p = 0.007) 
(Table 1). Also, patients with positive hormone receptors 
had higher LINC00472 expression compared to those 
Table 1: Associations of LINC00472 with Clinicopathological Factors in Turin Study
Patient Features Total 
No. (%)
Low LincRNA 
No. (%)
Mid LincRNA 
No. (%)
High LincRNA 
No. (%)
P value
Disease Stage 346    0.007
 Stage 1 128 (36.99) 18 (14.06) 71 (55.47) 39 (30.47)
 Stage 2 183 (52.89) 58 (16.76) 83 (23.99) 42 (22.95)  
 Stage 3 & 4 35 (10.12) 10 (28.57) 19 (54.29) 6 (17.14)  
Tumor Grade 343    < 0.0001
 Grade 1 57 (16.62) 3 (5.26) 27 (47.37) 27 (47.37)
 Grade 2 141 (41.11) 22 (15.60) 80 (56.74) 39 (27.66)  
 Grade 3 145 (42.27) 62 (42.76) 62 (42.76) 21 (14.48)  
Histology Type 347    0.043
 Ductal 219 (63.11) 65 (29.68) 103 (47.03) 51 (23.29)
 Lobular 56 (16.14) 6 (10.71) 29 (51.79) 21 (37.50)  
 Mix 35 (10.09) 6 (17.14) 21 (60.00) 8 (22.86)  
 Others 37 (10.66) 10 (27.03) 20 (54.05) 7 (18.92)  
ER Status 342    < 0.0001
 Positive 222 (64.91) 32 (14.41) 118 (53.15) 72 (32.43)
 Negative 120 (35.09) 54 (45.00) 51 (42.50) 15 (12.50)  
PR Status 341    < 0.0001
 Positive 178 (52.20) 26 (14.61) 98 (55.06) 54 (30.34)
 Negative 163 (47.80) 59 (36.20) 71 (43.56) 33 (20.25)  
(Continued )
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with negative receptor status ( p < 0.0001 for ER or PR) 
(Table 1). Furthermore, patients with high expression had 
better responses to adjuvant chemotherapy ( p = 0.021) 
and hormonal therapy ( p = 0.003) than those with low 
expression (Table 1). Finally, survival analysis suggested 
that patients with high expression had better disease-free 
( p < 0.001) and overall survival ( p = 0.005) compared 
to those with low expression (Figures 1A, 1B, and 
Table 2). Risk reduction in relapse was also observed 
when disease stage, tumor grade, receptor status and other 
clinical features of the patients were adjusted in analysis 
( p = 0.043) (Table 2).
Meta-analysis of GEO data
Twenty-seven datasets containing clinicopathologic 
information were identified in the GEO database 
(Supplementary Table S1). In a meta-analysis, we found 
higher LINC00472 expression to be associated with well-
differentiated tumors (low grades) and less aggressive 
disease (positive ER or PR, negative lymph nodes, luminal 
A and normal-like molecular subtypes) (Figures 2A, 2B). In 
GEO, 4 datasets compared gene expression between normal 
breast tissues and tumors. The comparison showed higher 
LINC00472 in normal than in tumor tissues (Supplementary 
Figure S2). Furthermore, 15 datasets in GEO contained 
information on various survival outcomes, of which 12 
included more than 100 patients individually. We performed 
survival analysis on these 12 datasets after LINC00472 
expression was grouped into 3 categories similar to those 
of our own study. Of the 12 studies, 9 showed significant 
individual associations between high LINC00472 and 
favorable survival outcomes (Supplementary Figure S3). 
Meta-analysis showed both overall survival (Figure 3A) 
and disease-free survival (Figure 3B) were significantly 
improved in patients with high LINC00472 compared to 
those with low expression. Overall, the results of these 
analyses were in agreement with our own study.
In vitro experiments
To examine the effect of LINC00472 on breast 
cancer cells, we analyzed LINC00472 expression in 
MCF7 and SKBR3, and found that the expression was 
low in these cell lines. We created an expression vector, 
pCDH_LINC00472 (Supplementary Figure S4), and 
transfected the vector into breast cancer cells to increase 
LINC00472 expression. The transfection was successful 
based on the GFP signal and RT-qPCR analysis (Figure 4). 
Cell proliferation assays showed that LINC00472 
expression significantly inhibited tumor cell growth 
(Figure 4). Furthermore, in the cell migration experiments, 
we found that both MCF7 and SKBR3 cell lines exhibited 
reduced migration after being transfected with LINC00472 
expressing vectors (Figure 5). These in vitro experiments 
suggest that increased LINC00472 expression may 
Patient Features Total 
No. (%)
Low LincRNA 
No. (%)
Mid LincRNA 
No. (%)
High LincRNA 
No. (%)
P value
Nodal Status 347    0.475
 Positive 160 (46.11) 45 (28.13) 77 (48.13) 38 (23.75)
 Negative 187 (53.89) 42 (22.46) 96 (51.34) 49 (26.20)
Tumor Size 346    < 0.0001
 T1 201 (58.09) 31 (15.42) 106 (52.74) 64 (31.84)  
 T2 120 (34.68) 46 (38.33) 54 (45.00) 20 (16.67)  
 T3/T4 25 (7.23) 9 (36.00) 13 (52.00) 3 (12.00)  
Adjuvant Endo-
therapy 173    0.003
 Complete Response 135 (78.03) 17 (12.59) 71 (52.59) 47 (34.81)
  No complete 
response 38 (21.97) 13 (34.21) 19 (50) 6 (15.79)  
Adjuvant Chemo-
therapy 219    0.021
 Complete Response 158 (72.15) 43 (27.22) 75 (47.47) 40 (25.32)
  No complete 
response 61 (27.85) 25 (40.98) 30 (49.18) 6 (9.84)  
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Figure 1: Associations of LINC00472 expression with patient survival in turin study. A. Kaplan-Meier estimates for  
disease-free survival by LINC00472 expression. B. Kaplan-Meier estimates for overall survival by LINC00472 expression.
A
B
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suppress tumor cell proliferation and migration, which is 
consistent with the findings of our clinical studies.
DISCUSSION
Our clinical study showed that LINC00472 
expression was significantly different by tumor grade, tumor 
size, disease stage, receptor status and molecular subtype. 
The expression was also associated with treatment response 
and survival outcomes, suggesting potential prognostic and 
predictive implications in clinical management of breast 
cancer. More importantly, our findings are very consistent 
across multiple datasets. This consistency is established 
on the basis of more than 20 independent studies which 
collectively included thousands of patients. The consistent 
finding was also based on two different laboratory methods, 
qPCR and microarray chips. Furthermore, our in vitro 
experiments on breast cancer cell lines supported the 
findings of our clinical studies. The overall consistency 
among multiple clinical studies and between in vivo and 
in vitro systems underscores the potential significance of 
LINC00472’s involvement in breast cancer, especially in 
tumor progression.
The gene encoding LINC00472 is located on 
chromosome 6q13, and the verified transcript has 2, 933 bp 
(NR_026807.1). The earlier annotation also contained a 
predicted transcript (XR_241853.1) that is longer than 
6,000 bp. We had designed two pairs of RT-qPCR primers 
to analyze both transcripts, and found that they were highly 
correlated (r = 0.76, p < 0.0001). Therefore, we chose the 
one which covers both transcripts for our measurement of 
expression in the study. Downstream from the LINC00472 
gene, there are two microRNA genes, miR30c and miR30a 
(Supplementary Figure S1), which have been reported to 
have possible effects on breast cancer invasion, metastasis 
and patient response to chemotherapy [36–42]. Although 
LINC00472 has not yet been functionally characterized 
for cellular activities or molecular processes, the results 
from multiple independent datasets and different platforms 
suggest that this lincRNA may behave like a tumor 
suppressor. Our in vitro experiments also indicates that 
LINC00472 can suppress cell proliferation and migration. 
We notice that the deletion of this gene is rare in the 
TCGA data [43, 44], and therefore the low expression of 
LINC00472 in breast cancer is likely due to the down-
regulation of expression. The biological mechanisms that 
control the expression of LINC00472 are still unknown.
Very recently a new clone (RP1–288M22) on 
chromosome 6q12–13 was submitted to NCBI. This clone 
expands the LINC00472 transcript to more than 9,000 bp 
(NR_026807.2) with three additional transcript variants 
of similar size. Our RT-qPCR primers were able to detect 
all four transcripts according to the NCBI Blast results 
(Supplementary Figure S5). Concerning the probes in the 
microarray chip from which the GEO data were generated, 
one probe (235771_at) represents the new clone. We 
compared the expression of this probe with the one used 
in our study (220324_at) in 15 datasets where data were 
available, and found a strong correlation of expression 
between these probes (Supplementary Figure S6), 
suggesting that our findings of LINC00472 expression 
in association with breast cancer based on 220324_at 
be applicable to the recent submission or renewal of 
LINC00472.
Long non-coding RNAs are suspected to exert their 
functions through interacting with ribonucleoprotein 
Table 2: Associations of LINC00472 with Breast Cancer Survival in Turin Study
Unadjusted Cox Regression Model
LincRNA HR1 for relapse 95% CI2 p value HR for death 95% CI p value
 Low 1   1   
 Mid 0.55 0.34–0.88 0.012 0.47 0.27–0.81 0.006
 High 0.28 0.14–0.58 < 0.001 0.34 0.16–0.72 0.005
 Continuous 0.54 0.39–0.74 < 0.001 0.55 0.38–0.80 0.002
Adjusted Cox Regression Model*
LincRNA HR for relapse 95% CI p value HR for death 95% CI p value
 Low 1   1   
 Mid 0.82 0.48–1.39 0.45 0.62 0.33–1.16 0.134
 High 0.44 0.20–0.97 0.043 0.51 0.21–1.22 0.129
 Continuous 0.70 0.48–1.00 0.050 0.69 0.45–1.07 0.098
*Adjusted for age, stage, grade, histology, ER, PR, nodal status and adjuvant treatment.
1HR: Hazards Ratio
2CI: Confidence Interval
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Figure 2: Meta-analysis of associations between LINC00472 expression and clinicopathological features of 
breast cancer. Summarized odds ratios were estimated using the random-effect model, and the odds ratio in each study was weighted 
with the variance of probe values (inverse-variance weighted method). A. Lower LINC00472 expression associated with high tumor grade 
(OR = 2.81; 95% CI: 2.24–3.53), positive lymph node (OR = 1.51; 95% CI: 1.22–1.87), or molecular subtypes of luminal B, Her2 positive 
and basal-like (OR = 3.80; 95% CI: 2.38–6.07).
(Continued )
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Figure 2 (Continued ): B. Higher LINC00472 expression associated with ER positive tumors (OR = 0.44; 95% CI: 0.35–0.57), PR positive 
tumors (OR = 0.44; 95% CI: 0.35–0.55), or Her2 negative tumors (OR = 2.62; 95% CI: 1.76–3.90).
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Figure 3: Meta-analysis of associations between LINC00472 expression and patient survival. A. Overall survival: 
HR = 0.91 (95% CI: 0.57–1.45) between mid and low LINC00472 expression (Upper Figure), and HR = 0.41 (95% CI: 0.22–0.78) between 
high and low LINC00472 expression (Lower Figure). B. Disease-free Survival: HR = 0.69 (95% CI: 0.55–0.88) between mid and low 
LINC00472 expression (Upper Figure), and HR = 0.43 (95% CI: 0.31–0.59) between high and low LINC00472 expression (Lower Figure).
A
B
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Figure 4: Effect of LINC00472 expression on breast cancer cell proliferation. A. GFP fluorescence images in MCF7 and 
SKBR3 cells transfected with pCDH or pCDH_LINC00472 vectors. B. RT-qPCR results of LINC00472 expression in MCF7 and SKBR3 
cells transfected with pCDH or pCDH_LINC00472 or mock transfected. C. Cell growth inhibition by LINC00472 in MCF7 cells. Twenty 
hours after seeding in 96-well plates, cells were transiently transfected with pCDH or pCDH_LINC00472 vectors, and kept in culture for up 
to 96 hours. Absorbance at 450nm of each well, which was directly proportional to the number of living cells in the well, was measured by 
SpectraMax M3 Multimode Plate Reader. The y axis showed the relative absorbance of corresponding wells from different days compared 
to that from day 0. Error bars represent SEM, n = 15. P values were determined by the Mann-Whitney U test. D. Inhibition of cell growth 
by LINC00472 in SKBR3 cells. The experiment and analysis are same as to those in C.
(RNP), but experimentally elucidating the actions of 
RNP complexes is difficult and time-consuming. To 
date, only a few RNP complexes have been characterized 
experimentally. Thus, computational prediction may 
be a valuable alternative to help predict the possible 
actions of LINC00472. We used a sequence-based 
method, catRAPID omics, to search for the binding 
proteins of LINC00472. Since catRAPID omics uses an 
algorithm that combines multiple features in addition 
to primary structure, its prediction is considered to be 
relatively reliable. Importantly this method has been 
used previously for testing several long non-coding 
RNAs, such as Xist, the long non-coding RNA X-inactive-
specific transcript, and the results of prediction have been 
consistent with experimental findings. The LINC00472-
binding proteome returned from the catRAPID omics 
analysis contained a total of 579 proteins, from which 127 
showed high interaction propensities (Interaction Strength 
> 50% and Discriminative Power > 75%, Z-score > 1.0) 
(Supplementary Figure S7). We uploaded these proteins 
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onto the Ingenuity Pathway Analysis (IPA) System for 
a core analysis using the Ingenuity Knowledge Base as 
a reference set. The IPA analysis suggested that proteins 
interacting with LINC00472 may involve several diseases 
and disorders, of which cancer is on top of the list 
(Supplementary Figure S7). IPA analysis also indicated 
that these proteins may be functionally involved in RNA 
post-transcriptional modification and protein synthesis 
and associated with 3 signaling networks where multiple 
biomarkers are known for breast cancer diagnosis, 
prognosis and treatment prediction (Supplementary 
Figures S8A–S8C). Knowing the potential RNA binding-
proteins may allow us not only to predict the possible 
targets of the lincRNA, but also to design additional 
experiments to assess its biologic functions.
Microarray technologies have substantially enhanced 
the search of biomarkers for cancer prognosis, but long 
non-coding RNAs in data generated by microarray analysis 
have not been well interrogated. Using GEO2R, an 
interactive web tool in GEO, we analyzed the relationships 
of LINC00472 expression and breast cancer characteristics 
in multiple GEO datasets generated from the most recent 
microarray chips, the Affymetrix Human Genome U133 
plus 2.0 array and the U133A array. Our finding of a 
consistent association between LINC00472 expression 
and breast cancer survival among various datasets 
supports the validity of this association and indicates such 
public databases invaluable to biomedical research. The 
consistency in the associations with clinicopathologic 
variables further strengthens the finding of our study.
Figure 5: Effect of LINC00472 expression on breast cancer cell migration. A. Microscopic views of cell migration before 
(0 hour) and after (24 hour) removal of stopper in SKBR3 and MCF7 cells transfected with pCDH or pCDH_LINC00472. Cells transfected 
with pCDH or pCDH_LINC00472 vectors formed monolayers in Oris 96-well plate and started to migrate to the exposed area after removing 
the stoppers in the well. Twenty-four hours later, the cells were fixed and stained with 0.1% crystal violet stain. The photomicrograph of 
the entire ‘wound’ area was taken under the IX71 inverted microscope with 4X objective lens. The representative wells were presented 
and the yellow circles indicated the areas previously occupied by stoppers. B. Measurements of absorbance after removal of stopper in 
SKBR3 and MCF7 cells transfected with pCDH or pCDH_LINC00472. With the detection mask, the absorbance at 590 nm wavelength of 
each well, which was directly proportional to the number of cells that migrated into the ‘wound’ area, was measured. The bar charts showed 
the average absorbance (y axis) from the wells with different cells after subtracting the background, the absorbance of the reference wells. 
Error bars represent SEM, n = 8. P values were determined by the Mann-Whitney U test.
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Overall, our investigation was based on multiple 
studies from diverse patient populations, and involved 
a large number of patients. We also demonstrated the 
results with different methods of lncRNA analysis 
(microarray and qPCR). These differences in patient 
populations and lab techniques lend strong support to 
our findings of LINC00472 in breast cancer. However, 
at present, very little is known about the exact functions 
of this long non-coding RNA. Therefore, we have not 
discussed the possible biologic mechanisms that may 
explain why LINC00472 behaves like a tumor suppressor. 
Whether our findings reflect direct effects of LINC00472 
on breast cancer or indirect actions via other molecules is 
unclear. More work is needed to elucidate the function of 
LINC00472 and its role in breast tumorigenesis.
MATERIALS AND METHODS
The role of LINC00472 in breast cancer was 
investigated through a) a clinical study in which we 
analyzed LINC00472 expression in 348 tumors using RT-
qPCR, b) meta-analysis of microarray data deposited in 
the GEO database, and c) manipulation of LINC00472 
expression in breast cancer cell lines.
Clinical study (Turin_Study)
Breast cancer patients
A clinical study of breast cancer was conducted in 
the University Hospital at University of Turin, in Italy, 
between January 1998 and July 1999. The study was 
approved by the university’s ethics review committee. 
During the study, 348 breast cancer patients were enrolled 
and provided informed consent. All study patients 
underwent surgical resection for breast cancer. Average 
age at surgery was 57 years (range: 23–84 years). Of the 
patients enrolled, 302 had follow-up information available 
through February 2007. Median follow-up was 86 months 
(range: 8–108 months). During follow-up, 81 patients 
developed recurrent or metastatic disease, and 55 of them 
died from the disease. A total of 60 died by the end of 
follow-up. Among the patients enrolled, 36.4% had 
Stage I disease (TMN), 53.4% had Stage II, and 10.3% 
had Stage III or IV. Patients diagnosed with Grade 1 
(well differentiated) tumors comprised 16.6%, Grade 2 
41.1%, and Grade 3 42.3%. Ductal carcinoma accounted 
for the majority of cases (63.1%), followed by lobular 
carcinoma (16.1%), other specific types (10.7%), and 
mixed histologic types (10.1%). Two hundred one patients 
(58.1%) had tumors smaller than 2 cm, 120 (34.7%) had 
tumors between 2 and 5 cm, and 25 (7.2%) had tumors 
greater than 5 cm. One hundred sixty patients (46.8%) 
had lymph node-positive tumors. Sixty-five percent of 
the patients had ER positive tumors, and 52.2% had PR 
positive tumors (at 10% cutoff for receptor positivity). 
Of the 348 patients, 303 received adjuvant therapy after 
surgery. Of those treated, 119 (34.2%) had chemotherapy, 
77 (22.1%) had hormonal therapy, and 107 (30.8%) 
received both. The chemotherapy protocols administered 
included CMF (cyclophosfamide, methotrexate, 
5 fluorouracil; 600/60/600 mg/mq every three weeks for six 
cycles), CEF (cyclophosfamide, epirubicin, 5 fluorouracil; 
600/90/600 mg/mq every three weeks for six cycles), EPI-
TAX (epirubicin-paclitaxel; 90/175 mg/mq every three 
weeks for six cycles),  EPI-VNB (epirubicin-vinorelbine; 
90/30 mg/mq every three weeks for six cycles), DTX-EPI-
VNB (doxetaxel-epirubicin-vinorelbine; 75/90/30 mg/mq 
every three weeks for six cycles), and TXT-EPI-VNB 
(paclitaxel-epirubicin-vinorelbine; 175/90/30 mg/mq 
every three weeks for cycles). Tamoxifen was the only 
agent used for endocrine therapy at that time. The dose 
was one 20 mg tablet per day for five years or until disease 
progression or intolerable toxicity.
Analysis of LINC00472 expression
Fresh tumor samples collected from patients during 
surgery were snap-frozen in liquid nitrogen immediately 
after resection and stored at -80°C until analysis. All tissue 
samples were examined by pathologists to confirm at least 
80% tumor content. The tissue samples (~30 mg each) were 
homogenized with ceramic beads in PowerLyzer (MO BIO), 
and processed to extract total RNA using Allprep DNA/RNA 
Kit (Qiagen). The RNA samples were treated with RNase-
free DNase and quantified using a spectrophotometer.
PCR primers were designed using the sequence 
NR_026807.1 (Supplementary Figure S1) and the 
synthesis was done by IDT (San Diego, CA). Total RNA 
(1 μg) was reverse transcribed using the cDNA Reverse 
Transcription Kit (LifeTech); RT-qPCR was performed in 
triplicate using SYBR Select Master Mix (LifeTech). In 
PCR reaction (10 μl), cDNA template (0.5 μl) was mixed 
with 200 nM primers and 5 μl SYBR PCR master mix. 
PCR conditions were incubation at 50oC for 2 min to 
activate UDG, 95oC for 2 min to activate Taq polymerase, 
and 40 cycles of 95oC for 15 s and 60oC for 1 min. 
LINC00472 measurement was normalized to GAPDH 
using the formula described in Statistical Analysis.
Meta-analysis of GEO data
Gene expression data generated from the Affymetrix 
Human Genome U133 plus 2.0 array and U133A array 
were selected from the GEO database. These datasets 
include 4, 628 breast cancer samples (Supplementary 
Table S1) and 193 normal breast tissues (Supplementary 
Figure S2). Expression data from probe 220324_at (which 
targets LINC00472) were used for meta-analysis, in which 
normalized expression was dichotomized using study-
specific median expression as cutoff to define “LINC00472_
higher” at or above median versus “LINC00472_lower” 
below median. Clinical and pathologic variables were also 
dichotomized. For each variable, summary odds ratios 
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and their 95% confidence intervals were estimated using 
the inverse variance weighted method. Because the meta-
analysis involved expression data assessed by different 
methods, we used the random-effects model. Forest plots 
were used to present the results. The meta-analysis was 
conducted with the use of Review Manager (Revman 
Version 5.3, Copenhagen, Denmark). Cochran χ2 test and 
I2 statistic were used to assess the heterogeneity among the 
studies involved. For datasets with more than 100 patients, 
Kaplan-Meier survival analyses were performed on 
individual studies (Supplementary Figure S3).
In vitro experiments
Preparation of LINC00472 Construct
A LINC00472 transcript (2933 bp, NR_026807.1) 
was assembled using the EST clones, EHS1001–
207275390, EHS1001–207498495, EHS1001–207533792, 
EHS1001–207590772, EHS1001–210281579, and 
EHS1001–211231922 (Thermo Scientific Open 
Biosystems). Restriction digestion sites for NheI and 
BamHI were incorporated into each site of the LINC00472 
transcript for cloning and verification. The entire 
sequence was inserted into a lentiviral expression 
vector, pCDH-EF1-MCS-pA-PGK-copGFP-T2A-Puro 
(System Biosciences). The construction was done by 
Science Exchange (Supplementary Figure S4). The clone 
authenticity was confirmed by restriction enzyme digestion 
(Supplementary Figure S4) and sequencing analysis.
Cell culture experiments
Breast cancer cell lines, SKBR3 and MCF-7, were 
a kind gift from Jun Panee (JABSOM, University of 
Hawaii) and were grown in DMEM medium containing 
10% FBS and 100 units/ml of penicillin/streptomycin 
(Pen/Strep). We transfected the cells with the LINC00472 
vector (pCDH_LINC00472), along with mock transfection 
and transfection of a control vector (pCDH). After 24 h 
incubation, cells were examined for GFP fluorescence; the 
evaluation was repeated in 48 h. After that, total RNA was 
extracted from the cells, and reverse-transcribed for qPCR 
analysis of LINC00472 expression which was normalized 
to GAPDH and compared between cells with different 
transfection conditions.
Cell proliferation assay
Twenty hours after seeding in 96-well plates, cells 
were transiently transfected with plasmids or  mock-
transfected, and kept growing for up to 96 h. At the end 
of each incubation period (24, 48, 72 and 96 h), numbers 
of viable cells were assessed by Cell Counting Kit-8 
(Sigma-Aldrich).
Cell migration assay
Cell migration was assessed with the modified 
Oris Cell Migration Assay (AMSBIO). After 24 hours of 
transfection with plasmids pCDH or pCDH_LINC00472, 
equal amount of cells were plated into the Oris 96-well 
plate which was incubated overnight with stoppers to 
permit cell attachment. Stoppers were removed from wells 
except the reference wells in which the stoppers were 
remained in place until results were read as pre-migration 
controls. Media was removed and wells were gently 
washed with sterile PBS. After that, fresh culture media 
was added to each well, and the plate was incubated for 
another 24 hours to allow for cell migration. The cultured 
cells were fixed and stained with 0.1% crystal violet stain. 
The photomicrograph of the entire wound area was taken 
using the IX71 inverted microscope with 4X objective 
lens. Using a detection mask, the absorbance at 590 nm 
wavelength in each well, which was directly proportional 
to the number of cells that migrated into the ‘wound’ area, 
was measured by a spectrophotometer (SpectraMax M3 
Multimode Plate Reader).
Statistical analysis
LINC00472 expression was calculated as an 
expression index (EI), using the formula 1,000 × 2(–ΔCt), 
where ΔCt = Ct (LINC00472) – Ct (GAPDH). For data 
analysis, EI was analyzed as a categorical variable with 3 
ordinal levels, low (< 25 percentile), Intermediate  (25–75 
percentile, labeled as “Mid” in Table 1), and high 
expression (> 75 percentile). Associations of LINC00472 
with clinical, pathologic and treatment variables and 
survival outcomes were determined using the Chi-square 
test or Cox proportional hazards regression model, 
as appropriate. Kaplan-Meier survival curves were 
constructed to show survival differences according to 
LINC00472 expression. The survival time for either overall 
or disease-free was calculated as the time from surgery 
until the occurrence of death and relapse, respectively. The 
Mann-Whitney U test was used for comparing differences 
in cell counts and migration. Spearman correlation 
coefficients were calculated for correlation analysis. All 
statistical tests were two-sided, and a p value less than 0.05 
was considered as statistical significance.
REFERENCES
1. Ferlay J SI, Ervik M, Dikshit R, Eser S, Mathers C, 
Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 
2012 v1.0, Cancer Incidence and Mortality Worldwide: 
IARC CancerBase No. 11 [Internet]. International Agency 
for Research on Cancer. 2013.
2. Bertos NR, Park M. Breast cancer - one term, many 
entities? The Journal of clinical investigation. 2011; 
121:3789–3796.
3. Burrell RA, McGranahan N, Bartek J, Swanton C. The 
causes and consequences of genetic heterogeneity in cancer 
evolution. Nature. 2013; 501:338–345.
Oncotarget13www.impactjournals.com/oncotarget
4. Roylance R, Endesfelder D, Gorman P, Burrell RA, Sander J, 
Tomlinson I, Hanby AM, Speirs V, Richardson AL, 
Birkbak NJ, Eklund AC, Downward J, Kschischo M, 
Szallasi Z, Swanton C. Relationship of extreme  chromosomal 
instability with long-term survival in a  retrospective  analysis 
of primary breast cancer. Cancer  epidemiology,  biomarkers & 
prevention: a  publication of the American Association for 
Cancer Research,  cosponsored by the American Society of 
Preventive Oncology. 2011; 20:2183–2194.
5. Stephens PJ, Tarpey PS, Davies H, Van Loo P, 
Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, 
Bignell GR, Yates LR, Papaemmanuil E, Beare D, Butler A, 
Cheverton A, Gamble J, et al. The landscape of cancer 
genes and mutational processes in breast cancer. Nature. 
2012; 486:400–404.
6. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, 
Harris CC, McLellan MD, Fulton RS, Fulton LL, 
Abbott RM, Hoog J, Dooling DJ, Koboldt DC, Schmidt H, 
Kalicki J, et al. Genome remodelling in a basal-like 
breast cancer metastasis and xenograft. Nature. 2010; 
464:999–1005.
7. Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, 
Greenman CD, Lau KW, Raine K, Jones D, Marshall J, 
Ramakrishna M, Shlien A, Cooke SL, Hinton J, Menzies A, 
Stebbings LA, Leroy C, et al. The life history of 21 breast 
cancers. Cell. 2012; 149:994–1007.
8. International Human Genome Sequencing C. Finishing the 
euchromatic sequence of the human genome. Nature. 2004; 
431:931–945.
9. Kapranov P, Willingham AT, Gingeras TR. Genome-wide 
transcription and the implications for genomic organization. 
Nature reviews Genetics. 2007; 8:413–423.
10. Huarte M, Rinn JL. Large non-coding RNAs: missing links 
in cancer? Human molecular genetics. 2010; 19:R152–161.
11. Ji P, Diederichs S, Wang W, Boing S, Metzger R, 
Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, 
Thomas M, Berdel WE, Serve H, Muller-Tidow C. 
MALAT-1, a novel noncoding RNA, and thymosin beta4 
predict metastasis and survival in early-stage non-small cell 
lung cancer. Oncogene. 2003; 22:8031–8041.
12. Huarte M, Guttman M, Feldser D, Garber M, Koziol MJ, 
Kenzelmann-Broz D, Khalil AM, Zuk O, Amit I, Rabani M, 
Attardi LD, Regev A, Lander ES, Jacks T, Rinn JL. A large 
intergenic noncoding RNA induced by p53 mediates global 
gene repression in the p53 response. Cell. 2010; 142:409–419.
13. Mourtada-Maarabouni M, Pickard MR, Hedge VL, 
Farzaneh F, Williams GT. GAS5, a non-protein-coding 
RNA, controls apoptosis and is downregulated in breast 
cancer. Oncogene. 2009; 28:195–208.
14. Yu W, Gius D, Onyango P, Muldoon-Jacobs K, Karp J, 
Feinberg AP, Cui H. Epigenetic silencing of tumour 
 suppressor gene p15 by its antisense RNA. Nature. 2008; 
451:202–206.
15. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, 
Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, Wang Y, 
Brzoska P, Kong B, Li R, West RB, van de Vijver MJ, 
et al. Long non-coding RNA HOTAIR reprograms 
 chromatin state to promote cancer metastasis. Nature. 2010; 
464:1071–1076.
16. Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, 
Cao Q, Brenner JC, Laxman B, Asangani IA, Grasso CS, 
Kominsky HD, Cao X, Jing X, Wang X, Siddiqui J, Wei JT, 
Robinson D, et al. Transcriptome sequencing across a 
prostate cancer cohort identifies PCAT-1, an  unannotated 
 lincRNA implicated in disease progression. Nature 
 biotechnology. 2011; 29:742–749.
17. Wang X, Arai S, Song X, Reichart D, Du K, Pascual G, 
Tempst P, Rosenfeld MG, Glass CK, Kurokawa R. Induced 
ncRNAs allosterically modify RNA-binding proteins in cis 
to inhibit transcription. Nature. 2008; 454:126–130.
18. Feng J, Bi C, Clark BS, Mady R, Shah P, Kohtz JD. 
The Evf-2 noncoding RNA is transcribed from the 
 Dlx-5/6 ultraconserved region and functions as a Dlx-2 
transcriptional coactivator. Genes & development. 2006; 
20:1470–1484.
19. Martianov I, Ramadass A, Serra Barros A, Chow N, 
Akoulitchev A. Repression of the human dihydrofolate 
reductase gene by a non-coding interfering transcript. 
Nature. 2007; 445:666–670.
20. Mariner PD, Walters RD, Espinoza CA, Drullinger LF, 
Wagner SD, Kugel JF, Goodrich JA. Human Alu RNA 
is a modular transacting repressor of mRNA transcription 
 during heat shock. Molecular cell. 2008; 29:499–509.
21. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, 
Brugmann SA, Goodnough LH, Helms JA, Farnham PJ, 
Segal E, Chang HY. Functional demarcation of active and 
silent chromatin domains in human HOX loci by noncoding 
RNAs. Cell. 2007; 129:1311–1323.
22. Nagano T, Mitchell JA, Sanz LA, Pauler FM, 
 Ferguson-Smith AC, Feil R, Fraser P. The Air noncoding 
RNA  epigenetically silences transcription by targeting G9a 
to chromatin. Science. 2008; 322:1717–1720.
23. Pandey RR, Mondal T, Mohammad F, Enroth S, Redrup L, 
Komorowski J, Nagano T, Mancini-Dinardo D, Kanduri C. 
Kcnq1ot1 antisense noncoding RNA mediates  lineage-specific 
transcriptional silencing through  chromatin-level regulation. 
Molecular cell. 2008; 32:232–246.
24. Yap KL, Li S, Munoz-Cabello AM, Raguz S, Zeng L, 
Mujtaba S, Gil J, Walsh MJ, Zhou MM. Molecular interplay 
of the noncoding RNA ANRIL and methylated histone H3 
lysine 27 by polycomb CBX7 in transcriptional silencing of 
INK4a. Molecular cell. 2010; 38:662–674.
25. Zhou Y, Zhong Y, Wang Y, Zhang X, Batista DL, 
Gejman R, Ansell PJ, Zhao J, Weng C, Klibanski A. 
Activation of p53 by MEG3 non-coding RNA. The Journal 
of biological chemistry. 2007; 282:24731–24742.
Oncotarget14www.impactjournals.com/oncotarget
26. Prasanth KV, Prasanth SG, Xuan Z, Hearn S, Freier SM, 
Bennett CF, Zhang MQ, Spector DL. Regulating gene 
expression through RNA nuclear retention. Cell. 2005; 
123:249–263.
27. Bernard D, Prasanth KV, Tripathi V, Colasse S, 
Nakamura T, Xuan Z, Zhang MQ, Sedel F, Jourdren L, 
Coulpier F, Triller A, Spector DL, Bessis A. A long 
nuclear-retained non-coding RNA regulates  synaptogenesis 
by modulating gene expression. The EMBO journal. 
2010; 29:3082–3093.
28. Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, 
Freier SM, Bennett CF, Sharma A, Bubulya PA, 
Blencowe BJ, Prasanth SG, Prasanth KV. The nuclear-
retained noncoding RNA MALAT1 regulates alternative 
splicing by modulating SR splicing factor phosphorylation. 
Molecular cell. 2010; 39:925–938.
29. Wilusz JE, Freier SM, Spector DL. 3′ end processing of a 
long nuclear-retained noncoding RNA yields a tRNA-like 
cytoplasmic RNA. Cell. 2008; 135:919–932.
30. Penny GD, Kay GF, Sheardown SA, Rastan S, 
Brockdorff N. Requirement for Xist in X chromosome 
 inactivation. Nature. 1996; 379:131–137.
31. Fitzpatrick GV, Soloway PD, Higgins MJ. Regional loss of 
imprinting and growth deficiency in mice with a targeted 
deletion of KvDMR1. Nature genetics. 2002; 32:426–431.
32. Sleutels F, Zwart R, Barlow DP. The non-coding Air RNA 
is required for silencing autosomal imprinted genes. Nature. 
2002; 415:810–813.
33. Li L, Liu B, Wapinski OL, Tsai MC, Qu K, Zhang J, 
Carlson JC, Lin M, Fang F, Gupta RA, Helms JA, 
Chang HY. Targeted disruption of Hotair leads to  homeotic 
transformation and gene derepression. Cell reports. 
2013; 5:3–12.
34. Zhang B, Arun G, Mao YS, Lazar Z, Hung G, 
Bhattacharjee G, Xiao X, Booth CJ, Wu J, Zhang C, 
Spector DL. The lncRNA Malat1 is dispensable for mouse 
development but its transcription plays a cis-regulatory role 
in the adult. Cell reports. 2012; 2:111–123.
35. Mungall AJ, Palmer SA, Sims SK, Edwards CA, 
Ashurst JL, Wilming L, Jones MC, Horton R, Hunt SE, 
Scott CE, Gilbert JG, Clamp ME, Bethel G, Milne S, 
Ainscough R, Almeida JP, et al. The DNA sequence 
and analysis of human chromosome 6. Nature. 2003; 
425:805–811.
36. Bockhorn J, Yee K, Chang YF, Prat A, Huo D, 
Nwachukwu C, Dalton R, Huang S, Swanson KE, 
Perou CM, Olopade OI, Clarke MF, Greene GL, Liu H. 
MicroRNA-30c targets cytoskeleton genes involved in 
breast cancer cell invasion. Breast cancer research and 
 treatment. 2013; 137:373–382.
37. Zhou H, Xu X, Xun Q, Yu D, Ling J, Guo F, Yan Y, Shi J, 
Hu Y. microRNA-30c negatively regulates endometrial 
cancer cells by targeting metastasis-associated gene-1. 
Oncology reports. 2012; 27:807–812.
38. Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, 
Yee K, Chang YF, Huo D, Wen Y, Swanson KE, Qiu T, 
Lu J, Park SY, Dolan ME, Perou CM, Olopade OI, 
et al. MicroRNA-30c inhibits human breast tumour 
 chemotherapy resistance by regulating TWF1 and IL-11. 
Nature communications. 2013; 4:1393.
39. Rodriguez-Gonzalez FG, Sieuwerts AM, Smid M, 
Look MP, Meijer-van Gelder ME, de Weerd V, Sleijfer S, 
Martens JW, Foekens JA. MicroRNA-30c expression 
level is an independent predictor of clinical benefit of 
endocrine therapy in advanced estrogen receptor positive 
breast  cancer. Breast cancer research and treatment. 2011; 
127:43–51.
40. Franzetti GA, Laud-Duval K, Bellanger D, Stern MH, 
Sastre-Garau X, Delattre O. MiR-30a-5p connects EWS-
FLI1 and CD99, two major therapeutic targets in Ewing 
tumor. Oncogene. 2013; 32:3915–3921.
41. Baraniskin A, Birkenkamp-Demtroder K, Maghnouj A, 
Zollner H, Munding J, Klein-Scory S, Reinacher-Schick A, 
Schwarte-Waldhoff I, Schmiegel W, Hahn SA. MiR-30a-5p 
suppresses tumor growth in colon carcinoma by targeting 
DTL. Carcinogenesis. 2012; 33:732–739.
42. Zhang N, Wang X, Huo Q, Sun M, Cai C, Liu Z, Hu G, 
Yang Q. MicroRNA-30a suppresses breast tumor growth 
and metastasis by targeting metadherin. Oncogene. 2014; 
33:3119–3128.
43. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, 
Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, 
Cerami E, Sander C, Schultz N. Integrative analysis of 
complex cancer genomics and clinical profiles using the 
cBioPortal. Science signaling. 2013; 6:pl1.
44. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, 
Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, 
Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. 
The cBio cancer genomics portal: an open platform for 
exploring multidimensional cancer genomics data. Cancer 
 discovery. 2012; 2:401–404.
